The rapid growth of GLP-1 receptor agonists, dual agonists and other emerging therapies is accelerating drug development across obesity and type 2 diabetes. At the same time, sponsors face increasing pressure to demonstrate more than just weight loss or glycemic control. This webinar will explore how phase-appropriate endpoint strategies can support stronger development decisions and more differentiated evidence across obesity clinical trials. Development teams increasingly need to understand how a therapy affects the whole patient, including symptoms, treatment experience, glucose patterns, body composition, organ health and cardiovascular safety. However, the questions sponsors need to confidently answer in early-phase trials differ from those addressed in larger Phase II and Phase III programs. Join the featured experts in eCOA, cardiac safety and medical imaging to learn how phase-appropriate endpoint solutions that generate high-quality, informative data can support critical decisions. From detecting early safety and efficacy signals informing dose selection, go/no-go and study design decisions, to characterizing treatment benefit and risk building a differentiated, regulator-ready evidence package, implementing the right endpoint strategy and technologies is paramount. Register to learn how an integrated, phase-appropriate endpoint strategy can help teams identify meaningful signals earlier, reduce development uncertainty and generate stronger evidence for regulatory review and product differentiation.